Compare Robinhood Markets, Inc. (HOOD) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Robinhood Markets, Inc. vs Novo Nordisk A/S — how do they compare? Robinhood Markets, Inc. trades at $108.89 (market cap $96.21B), while Novo Nordisk A/S trades at $38.44 (market cap $165.31B). The key difference: Novo Nordisk A/S is the larger of the two by market cap, and Novo Nordisk A/S pays a 4.71% dividend while Robinhood Markets, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Robinhood Markets, Inc. for 75 Days and Novo Nordisk A/S for 116 Days on average.
| HOOD | NVO | |
|---|---|---|
Market Cap | $96.21B | $165.31B |
Volume | 22,572,153 | 11,432,838 |
Sector | Financials | Health |
52-Week High | $152.46 | $63.98 |
52-Week Low | $65.16 | $35.29 |
Typical Hold Time | 75 Days | 116 Days |
Enterprise Value | $102.75B | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Robinhood (HOOD) trades at $108.95, down 0.51% on the day, with a bullish technical signal and strong analyst consensus. The stock shows robust fundamentals with 2025 revenue of $4.47B and net income of $1.88B, though valuation ratios like P/E of 47.35 are elevated. Recent news highlights expansion into 24/7 stock trading and AI-driven features, signaling growth initiatives.
Outlook remains positive with a consensus price target of $137.53, offering ~26% upside, but risks include high valuation sensitivity and competitive pressures in the brokerage sector. Earnings beat in two of the last three quarters supports growth trajectory, though investors should monitor execution on new product launches and regulatory developments.
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Robinhood Markets, Inc.
Robinhood Markets, Inc. operates a financial services platform. The Company offers brokerage and cash management applications such as stocks, exchange-traded funds, options, and cryptocurrency. Robinhood Markets serves clients in the United States.
Read more on HOOD →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
